Biocon Biologics' biosimilar sites cleared by FDA 16-Apr-2020 By Ben Hargreaves The company announces that an inspection by the US FDA into its two sites had now been closed.
Biocon insulin facility hit with FDA Form 483 27-Feb-2020 By Ben Hargreaves Biocon’s Malaysia facility received a Form 483 with three observations, after a pre-approval inspection.
Biocon biosimilar business valued at $3bn in funding round 14-Jan-2020 By Nick Taylor Biocon Biologics receives True North investment that values biosimilar business at around $3bn.
